Being diagnosed with a potentially fatal disease usually triggers immediate treatment. But a growing number of people infected with hepatitis C are putting off therapy, choosing instead to roll the dice and wait for a new generation of drugs to become available.
FDA promised not to enforce the NDI guidance until it was final. Last Friday, they broke that promise.
Sent: Friday, March 16, 2012 4:03 PM
To: Lloyd Wright
Was just getting ready to order VEP 2 and a tea package in the next day or so. As it happens, I was with a close friend of mine who is sick and in a similar condition. Maybe worse, since he has diabetes. And doesn’t eat or exercise obsessively, as I do.
Shares of Gilead Sciences (GILD: 44.69, -2.31, -4.91%) fell 14% Friday morning after the drug maker said a majority of patients enrolled in one of its studies experienced a viral relapse within four weeks of completing the 12-week experimental hepatitis C treatment.
Six of the eight patients that previously had a “null” response but were taking GS-7977 plus the widely used antiviral ribavirin as part of Gilead’s Electron study had a relapse.
by Stuart Lindsey, PharmD.
When an insider breaks ranks with pharmaceutical orthodoxy, it is time to take notice. "Whistleblower" may be an overused term, but the article that follows might be well worth readers' consideration before standing in line for their next prescription refill. - Andrew W. Saul, OMNS Editor
Yesterday, January 9, 2012 Inhibitex, makers of an oral hep c drug was purchased by Bristol Myers for 2.5 Billion dollars.
On Squawk Box, CNBC, Kramer said, I don’t get it, hep c is a horrible disease, it is fatal but not a big deal. He said, I don’t get it, why so much money is being paid for this oral phase 2 asset. Inhibitex stock went up 189 times over night. A terrific profit.
Russian scientists have developed an innovative drug that can cure hepatitis C within a month. They started their research in this area over 20 years ago and at present, they have patented the drug which will be available for sale next year.
The drug known as Profetal is based on human alpha-fetoprotein, says Alexander Petrov, head of the Ural Pharmaceutics Cluster, where the project is underway, in an interview with the Voice of Russia.
Greatest Threat Since FDA Tried to Turn
Nutrients into Prescription Drugs!
Sent: Sunday, July 17, 2011 2:57 PM
Subject: Long term disabilities from taking Roche Pegasys
I hope we all can get together and find an attorney to represent us in this situation. I have hep C. I contracted through a blood transfusion in 1989. I have the hardest version to treat geno-type 1. I did interferon treatment 7 days a week with riboshpere. Initial plan was a full year of interferon and with the chance of 65% Hep C of returning.
During the treatment. I was severely fatigued, broke out with sores, had a rash that burnt my skin leaving scars on my legs and feet, severely confused, developed hepatic encelopathy had my drivers license cancelled because during the hepatic encelopathy I did not know where I was, who I was or what I was doing. I was driving my car when I had a (HE) flair up and so DMV and the Dr.'s advised no more driving.